S-Target Therapeutics

s-target therapeutics is a biotech start-up that develops novel therapeutic vaccines to cure and prevent allergic diseases, based on the unique, proprietary s-tir technology platform. s-target‘s vaccines address the cause of the disease not only the symptoms. they are directed against major, widespread severe forms of allergic diseases that currently cannot be cured. lead candidate sg100 targets allergic asthma induced by house dust mite (hdm), the major cause of allergy in the western world. s-target therapeutics is a privately held company based in vienna austria. in april 2013 sg100 achieved in vivo proof of concept in non human primates. in may 2013 the proprietary s-tir technology platform for development of therapeutic vaccines in oncology was outlicensed to oncoqr ml og.